FCE 27270

Drug Profile

FCE 27270

Latest Information Update: 30 May 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pharmacia Corporation
  • Class Analgesics; Antiemetics; Antimigraines; Antipsychotics; Anxiolytics; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anxiety disorders; Nausea and vomiting; Psychotic disorders

Most Recent Events

  • 30 May 2001 Profile reviewed but no significant changes made
  • 03 Feb 1997 No-Development-Reported for Anxiety disorders in Italy (Unknown route)
  • 03 Feb 1997 No-Development-Reported for Emesis in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top